- cafead   Aug 28, 2024 at 11:42: AM
via Bayer entered a collaboration with NextRNA to develop two small molecules for cancer that work by targeting the interaction between disease-driving long non-coding RNAs (lncRNAs) and RNA-binding proteins, providing a point of validation for lncRNAs as a novel class of oncology targets.
article source
article source